Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Cortesi

Showing results (131-140 of 174) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord OvestAlfredo Falcone, Sergio Ricci, Isa Brunetti, et al.
Vaccine|March 18, 2024
COVID-19 vaccination in cancer patients: Immune responses one year after the third doseRoberta Campagna, Federica Dominelli, Maria Antonella Zingaropoli, et al.
The New England Journal of Medicine|October 23, 2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Gianluca Masi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamidePaola Papaldo, Massimo Lopez, Enrico Cortesi, et al.
The Oncologist|April 19, 2019
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World PopulationLucio Crinò, Paolo Bidoli, Angelo Delmonte, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2020
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223Orazio Caffo, Viviana Frantellizzi, Marcello Tucci, et al.
NPJ Breast Cancer|December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?Paola Papaldo, Gianluigi Ferretti, Serena Di Cosimo, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancerFrancesco Grossi, Carlo Genova, Lucio Crinò, et al.
Pageof 18

Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord OvestAlfredo Falcone, Sergio Ricci, Isa Brunetti, et al.
Vaccine|March 18, 2024
COVID-19 vaccination in cancer patients: Immune responses one year after the third doseRoberta Campagna, Federica Dominelli, Maria Antonella Zingaropoli, et al.
The New England Journal of Medicine|October 23, 2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Gianluca Masi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamidePaola Papaldo, Massimo Lopez, Enrico Cortesi, et al.
The Oncologist|April 19, 2019
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World PopulationLucio Crinò, Paolo Bidoli, Angelo Delmonte, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2020
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223Orazio Caffo, Viviana Frantellizzi, Marcello Tucci, et al.
NPJ Breast Cancer|December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?Paola Papaldo, Gianluigi Ferretti, Serena Di Cosimo, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancerFrancesco Grossi, Carlo Genova, Lucio Crinò, et al.
Pageof 18